Multidisciplinary Association for Psychedelic Studies

Last updated
Multidisciplinary Association for Psychedelic Studies
MAPS.svg
AbbreviationMAPS  OOjs UI icon edit-ltr-progressive.svg
Established1986  OOjs UI icon edit-ltr-progressive.svg (38 years ago)
Founders Rick Doblin   OOjs UI icon edit-ltr-progressive.svg
Types nonprofit organization   OOjs UI icon edit-ltr-progressive.svg
Legal status 501(c)(3) organization   OOjs UI icon edit-ltr-progressive.svg
CountryUnited States  OOjs UI icon edit-ltr-progressive.svg
Revenue19,288,186 United States dollar (2018)  OOjs UI icon edit-ltr-progressive.svg
Website maps.org   OOjs UI icon edit-ltr-progressive.svg

The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.

Contents

MAPS helps scientists design, fund, and obtain regulatory approval for studies of the safety and effectiveness of a number of controlled substances. MAPS works closely with government regulatory authorities worldwide such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to ensure that all of its sponsored research protocols conform to ethical and procedural guidelines for clinical drug research. Included in MAPS' research efforts are MDMA (methylenedioxymethamphetamine) for the treatment of posttraumatic stress disorder (PTSD); LSD and psilocybin for the treatment of anxiety, cluster headaches, and depression associated with end-of-life issues; ibogaine for the treatment of opiate addiction, ayahuasca for the treatment of drug addiction and PTSD; medical cannabis for PTSD; and alternative delivery systems for medical cannabis such as vaporizers and water pipes. MAPS officials say the organization's ultimate goal is to establish a network of clinics where these and other treatments can be provided together with other therapies under the guidance of trained, licensed physicians and therapists. [1] In December 2023, MAPS submitted a New Drug Application (NDA) to the FDA for MDMA-assisted psychotherapy. [2]

In addition to sponsoring scientific research, MAPS organizes continuing medical education (CME) conferences, sponsors and presents lectures and seminars on the state of psychedelic and medical marijuana research, provides psychedelic harm reduction services through the Zendo Project at events such as music festivals and Burning Man, and publishes a triannual magazine-style publication, the MAPS Bulletin, with updates about its ongoing research efforts, legal struggles, and educational initiatives. MAPS also publishes books dealing with the science, history, and culture of psychedelic research and psychedelic therapy. [3]

History

Founding MAPS

Anticipating that the Drug Enforcement Administration (DEA) would move to criminalize MDMA in light of the drug's increasing popularity in recreational use, Rick Doblin, Alise Agar and Debby Harlow organized a nonprofit group called Earth Metabolic Design Laboratories (EMDL) to advocate for the potential therapeutic use of MDMA. By 1984 the DEA had announced its intention to designate MDMA as a Schedule I substance, a categorization that would greatly restrict and regulate the drug's availability, as well as indicate that it held no accepted medical use and a high abuse potential. [4]

EMDL organized supporters to petition the DEA for a scheduling hearing regarding MDMA. George Greer, Lester Grinspoon, Professor James Bakalar, and Professor Thomas Roberts contributed to the argument that MDMA belonged in Schedule III, a category that would more readily enable future research and permit the continuation of its use in psychotherapy. Despite such efforts, the DEA pursued emergency scheduling in 1985, citing an imminent risk to public health.[ citation needed ]

As MDMA was now deemed illegal, held in the same category as such substances as heroin, the only way for it to be employed in scientific inquiry would be through the lengthy and expensive FDA approval process. Holding the belief that MDMA had the unique potential both to aid psychotherapy and eventually to become a prescription medicine, Rick Doblin sought to gain incorporation for MAPS as a 501(c)(3) nonprofit research and educational organization. The founding of MAPS was a primary step toward the future envisioning of what Doblin has called a "nonprofit psychedelic-pharmaceutical company." [5] Chartered in 1986, MAPS has since contributed over 12 million dollars towards the scientific study of psychedelics and cannabis in therapeutic applications. [6] [7]

Controversies

In 2022, video of MAPS therapists spooning and pinning down a clinical trial participant in a phase 2 trial for MDMA for PTSD emerged as part of the reporting for the Cover Story: Power Trip podcast by New York Magazine and Psymposia. [8] Following treatment, one of the therapists sexually coerced the patient and the patient moved to live with the therapists for two years.

In 2019, MAPS had claimed that "Monitoring of study records throughout the course of the trial and afterwards did not indicate signs of ethical violation....The protective measures in place include having two therapy providers in every therapy visit, video recording of all therapy visits, monitoring of study and therapy activities, and clinical supervision. In this case, none of these measures were sufficient." [9] However, in 2022, MAPS spokesperson Betty Aldworth claimed that MAPS staff did not actually view the videos until November 2021, following an interview with Rick Doblin for Cover Story: Power Trip. [10]

Projects

Since 1986, MAPS has distributed over $20 million to fund psychedelics and medical cannabis research and education. These include:

Organization

Board and staff

MAPS is governed by a board of directors including John Gilmore, David Bronner, Robert J. Barnhart, and Rick Doblin. Ashawna Hailey served on the board until her death in 2011.

Funding

MAPS is a nonprofit 501(c)(3) research and educational organization, funded by donations from individuals and foundations. [18] Donations to MAPS can be restricted to fund a specific project, or be unrestricted. [19] MAPS also receives revenue from conferences and events, such as the Psychedelic Science conference, as well as from the sale of books, merchandise, and art. [20] With a policy of transparency in financial matters, MAPS publishes a detailed annual financial report. [21] On August 20, 2020, having raised $30 million in non-profit donations in less than six months, MAPS and the Psychedelic Science Funders Collaborative (PSFC) announced the completion of the Capstone Campaign, a non-profit fundraising effort to fund the final research required to seek U.S. Food and Drug Administration (FDA) approval of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). [22] [23]

Medical cannabis monopoly

National Institute on Drug Abuse (NIDA) has a government granted monopoly on the production of cannabis for medical research purposes. [24] In the past, the institute has refused to supply marijuana to researchers who had obtained all other necessary federal permits. Medical marijuana researchers and activists claim that NIDA, which is not supposed to be a regulatory organization, does not have the authority to effectively regulate who does and doesn't get to do research with medical marijuana. Jag Davies of the Multidisciplinary Association for Psychedelic Studies (MAPS) writes in MAPS Bulletin:

Currently, the National Institute on Drug Abuse (NIDA) has a monopoly on the supply of research-grade marijuana, but no other Schedule I drug, that can be used in FDA-approved research. NIDA uses its monopoly power to obstruct research that conflicts with its vested interests. MAPS had two of its FDA-approved medical marijuana protocols rejected by NIDA, preventing the studies from taking place. MAPS has also been trying without success for almost four years to purchase 10 grams of marijuana from NIDA for research into the constituents of the vapor from marijuana vaporizers, a non-smoking drug delivery method that has already been used in one FDA-approved human study.

—  [25]

NIDA administers a contract with the University of Mississippi to grow the nation's only legal cannabis crop for medical and research purposes, [26] including the Compassionate Investigational New Drug program. United States federal law registers cannabis as a Schedule I drug. Medical marijuana researchers typically prefer to use high-potency marijuana, but NIDA's National Advisory Council on Drug Abuse has been reluctant to provide cannabis with high THC levels, citing safety concerns: [26]

Most clinical studies have been conducted using cannabis cigarettes with a potency of 2-4% THC. However, it is anticipated that there will be requests for cannabis cigarettes with a higher potency or with other mixes of cannabinoids. For example, NIDA has received a request for cigarettes with an 8% potency. The subcommittee notes that very little is known about the clinical pharmacology of this higher potency. Thus, while NIDA research has provided a large body of literature related to the clinical pharmacology of cannabis, research is still needed to establish the safety of new dosage forms and new formulations. In the most recent rejection of medical marijuana by the Federal Government, the DEA denied Professor Craker, Valerie Corral, and MAPS request to end the federal governments monopoly on medical marijuana production and research.

—  [27]

Major events in recent proceedings are notable, as in the 2007 ruling by Administrative Law Judge Mary Ellen Bittner, wherein she recommended that Craker receive a license to grow marijuana for research and that NIDA dismantle its monopoly. The DEA in response overturned the recommended ruling in January 2009, and later denied Craker's Motion to Reconsider in December 2010. In March 2011, Craker's lawyers submitted their final brief in the case. MAPS is pursuing efforts to have the DEA's final ruling rescinded. [12] A detailed timeline of MAPS' attempts to gain access to research grade marijuana is available on the MAPS website.

In 2016, the Obama administration DEA announced their intent to grant additional licenses to marijuana growers for research, ending the NIDA monopoly on federally legal marijuana. [28] The DEA finalized the proposed rule in early 2020. [29]

See also

Related Research Articles

<span class="mw-page-title-main">MDMA</span> Psychoactive drug, often called ecstasy

3,4-Methyl​enedioxy​methamphetamine (MDMA), commonly known as ecstasy, and molly or mandy, is a potent empathogen–entactogen with stimulant and minor psychedelic properties. Investigational indications include as an adjunct to psychotherapy in the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autism spectrum disorder. The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours.

Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, LSD, and ayahuasca, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.

<span class="mw-page-title-main">Rick Doblin</span> American drug activist

Richard Elliot Doblin is an American drug activist and executive who is the founder and former executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

<span class="mw-page-title-main">National Institute on Drug Abuse</span> Branch of the National Institutes of Health in the United States

The National Institute on Drug Abuse (NIDA) is a United States federal government research institute whose mission is to "advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health."

The Beckley Foundation is a UK-based think tank and UN-accredited NGO, dedicated to activating global drug policy reform and initiating scientific research into psychoactive substances. The foundation is a charitable trust which collaborates with leading scientific and political institutions worldwide to design and develop research and global policy initiatives. It also investigates consciousness and its modulation from a multidisciplinary perspective, working in collaboration with scientists. The foundation is based at Beckley Park near Oxford, United Kingdom. It was founded in 1998, and is directed by Amanda Feilding, Countess of Wemyss.

<span class="mw-page-title-main">Drug policy of California</span> Overview of the drug policy of the U.S. state of California

Drug policy of California refers to the policy on various classes and kinds of drugs in the U.S. state of California. Cannabis possession has been legalized with the Adult Use of Marijuana Act, passed in November 2016, with recreational sales starting January of the next year. With respect to many controlled substances, terms such as illegal and prohibited do not include their authorized possession or sale as laid out by applicable laws.

<span class="mw-page-title-main">Medical cannabis in the United States</span> Use of cannabis for medical purposes in the United States

In the United States, the use of cannabis for medical purposes is legal in 38 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of March 2023. Ten other states have more restrictive laws limiting THC content, for the purpose of allowing access to products that are rich in cannabidiol (CBD), a non-psychoactive component of cannabis. There is significant variation in medical cannabis laws from state to state, including how it is produced and distributed, how it can be consumed, and what medical conditions it can be used for.

<span class="mw-page-title-main">Insight-oriented psychotherapy</span>

Insight-oriented psychotherapy is a category of psychotherapies that rely on conversation between the therapist and the client. It involves developing the patient's understanding of past and present experiences, how they are related to each other and the effect they have on the patient's interpersonal relationships, emotions and symptoms. Insight-oriented psychotherapy can be an intensive process, wherein the client must spend multiple days per week with the therapist.

PTSD or post-traumatic stress disorder, is a psychiatric disorder characterised by intrusive thoughts and memories, dreams or flashbacks of the event; avoidance of people, places and activities that remind the individual of the event; ongoing negative beliefs about oneself or the world, mood changes and persistent feelings of anger, guilt or fear; alterations in arousal such as increased irritability, angry outbursts, being hypervigilant, or having difficulty with concentration and sleep.

<span class="mw-page-title-main">Julie Holland</span> Author, psychiatrist and psychoparmacologist

Julie Holland is an American psychopharmacologist, psychiatrist, and author. She is the author of five books, including Weekends at Bellevue: Nine Years on the Night Shift at the Psych ER, a memoir documenting her experience as the weekend head of the psychiatric emergency room at Bellevue Hospital in New York City An advocate for the appropriate use of consciousness expanding substances as part of mental health treatment, she is a medical monitor for MAPS studies, which involve, in part, developing psychedelics into prescription medication.

Psynapse is a nonprofit organization based in Oslo, Norway, which aims to increase access to MDMA and psychedelics for medical and scientific purposes, as well as advocating for the legalization of psychedelics for human rights reasons. Psynapse was founded in 2015 by researchers Pål-Ørjan Johansen and his wife, Teri Krebs.

The Spring Grove Experiment is a series of lysergic acid diethylamide (LSD) studies performed from 1963 to 1976 on patients with psychotic illnesses at the Spring Grove Clinic in Catonsville, Maryland. These patients were sponsored by a federal agency called the National Institute of Mental Health to be part of the first study conducted on the effects of psychedelic drugs on people with schizophrenia. The Spring Grove Experiments were adapted to study the effect of LSD and psychotherapy on patients including alcoholics, heroin addicts, neurotics, and terminally-ill cancer patients. The research done was largely conducted by the members of the Research Unit of Spring Grove State Hospital. Significant contributors to the experiments included Walter Pahnke, Albert Kurland, Sanford Unger, Richard Yensen, Stanislav Grof, William Richards, Francesco Di Leo, and Oliver Lee McCabe. Later, Spring Grove was rebuilt into the Maryland Psychiatric Research Center where studies continued to be performed for the advancement of psychiatric research. This study on LSD is the largest study on psychedelic drugs to date.

Medical cannabis research includes any medical research on using cannabis. Different countries conduct and respond to medical cannabis research in different ways.

<span class="mw-page-title-main">Psilocybin therapy</span> Experimental use of psilocybin to treat anxiety & depression

Psilocybin therapy is the use of psilocybin in treating a range of mental health conditions, such as depression, anxiety, addictions, obsessive compulsive disorder, and psychosis. It is one of several forms of psychedelic therapy under study. Psilocybin was popularized as a psychedelic recreational drug in the 1970s and was classified as a Schedule I drug by the DEA. Research on psilocybin as a medical treatment was restricted until the 1990s because of the sociocultural fear of dependence on this drug. As of 2022, psilocybin is the most commonly researched psychedelic due to its safety and low potential for abuse and dependence. Clinical trials are being conducted at universities and there is evidence confirming the use of psilocybin in the treatment of depression, PTSD and end of life anxiety.

MDMA-assisted psychotherapy is the use of prescribed doses of MDMA as an adjunct to psychotherapy sessions. Research suggests that MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD), including Complex PTSD, might improve treatment effectiveness. In 2017, a Phase II clinical trial led to "breakthrough therapy" designation by the US Food and Drug Administration (FDA) for potential use as a treatment for PTSD.

<span class="mw-page-title-main">MindMed</span> Psychedelic medicine biotech company

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.

Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Several existing psychoplastogens have been identified and their therapeutic effects demonstrated; several are presently at various stages of development as medications including Ketamine, MDMA, Scopolamine, and the serotonergic psychedelics, including LSD, psilocin, DMT, and 5-MeO-DMT. Compounds of this sort are being explored as therapeutics for a variety of brain disorders including depression, addiction, and PTSD. The ability to rapidly promote neuronal changes via mechanisms of neuroplasticity was recently discovered as the common therapeutic activity and mechanism of action.

Psychedelic treatments for trauma-related disorders are the use of psychedelic substances, either alone or used in conjunction with psychotherapy, to treat trauma-related disorders. Trauma-related disorders, such as post-traumatic stress disorder (PTSD), have a lifetime prevalence of around 8% in the US population. However, even though trauma-related disorders can hinder the everyday life of individuals with them, less than 50% of patients who meet criteria for PTSD diagnosis receive proper treatment. Psychotherapy is an effective treatment for trauma-related disorders. A meta-analysis of treatment outcomes has shown that 67% of patients who completed treatment for PTSD no longer met diagnostic criteria for PTSD. For those seeking evidence-based psychotherapy treatment, it is estimated that 22-24% will drop out of their treatment. In addition to psychotherapy, pharmacotherapy (medication) is an option for treating PTSD; however, research has found that pharmacotherapy is only effective for about 59% of patients. Although both forms of treatment are effective for many patients, high dropout rates of psychotherapy and treatment-resistant forms of PTSD have led to increased research in other possible forms of treatment. One such form is the use of psychedelics.

Ketamine-assisted psychotherapy(KAP) is the use of prescribed doses of ketamine, the drug, as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. It can also be used for those experiencing substance abuse and physical pain. While it is primarily used as a veterinary anaesthetic, ketamine has also been found to have rapid analgesic and hallucinogenic effects, which has sparked interest in its use as an antidepressant. Despite initial trials of its use in the treatment of mental disorders focussing primarily on its antidepressant effects, newer studies are attempting to harness its psychedelic effects to bring about altered states of consciousness, which will augment the adjunct psychotherapy. Ketamine's neuroplasticity-promoting effects strengthen the cognitive restructuring that takes place through traditional psychotherapy, thereby leading to long-lasting behavioural change. KAP offers promising directions for research on new antidepressant alternatives, but is still not sufficiently defined or evaluated as a treatment combination.

Heroic Hearts Project is a registered 501(c)(3) nonprofit organization, functioning as a support group for US military veterans. The project engages psychedelic therapy to help people suffering a range of psychological maladies, such as PTSD, MST, severe depression, anxiety, etс. The organization has also been instrumental in the ongoing movement to change state and federal drug policies and overcome the stigma around them.

References

  1. ↑ Doblin R (2002). "A clinical plan for MDMA ("Ecstasy") in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA". Journal of Psychoactive Drugs. 34 (2): 185–94. CiteSeerX   10.1.1.545.1584 . doi:10.1080/02791072.2002.10399952. PMID   12691208. S2CID   11089345.
  2. ↑ Gilbert, Daniel; Ovalle, David (2023-12-13). "FDA to review MDMA-assisted therapy, a milestone for psychedelics". Washington Post. ISSN   0190-8286 . Retrieved 2024-02-05.
  3. 1 2 "Multidisciplinary Association for Psychedelic Studies". MAPS. Archived from the original on 2019-06-20. Retrieved 2019-06-20.
  4. ↑ Documents from the DEA Scheduling Hearing of MDMA, 1984-1988, Maps.org, archived from the original on 2012-05-23, retrieved 2012-04-14
  5. ↑ Millard, M. (October 8–14, 2004). "This is your brain on drugs: Rick Doblin thinks pot, ecstasy, and other psychedelics could unlock the human mind — and he wants to bring them to Harvard, the FDA, and a doctor's office near you". Boston Phoenix. Archived from the original on 20 November 2013. Retrieved 31 May 2014.
  6. ↑ Financial Reports, Maps.org, archived from the original on 2012-04-24, retrieved 2012-04-14
  7. ↑ Mission, Maps.org, archived from the original on 2012-04-14, retrieved 2012-04-14
  8. ↑ "You Won't Feel High After Watching This Video". 22 March 2022.
  9. ↑ "Statement: Public Announcement of Ethical Violation by Former MAPS-Sponsored Investigators". 25 May 2019.
  10. ↑ "Footage of therapists spooning and pinning down patient in B.C. trial for MDMA therapy prompts review". CBC News . 2022-04-09. Archived from the original on 2023-07-16.
  11. ↑ "MAPS/EROWID Psychedelic Bibliography Projects". www.maps.org. Archived from the original on 2014-04-18. Retrieved 2014-06-16.
  12. 1 2 3 4 Medical Marijuana, Maps.org, archived from the original on 2012-04-14, retrieved 2012-04-14
  13. ↑ Harris, Gardiner (18 January 2010). "Researchers find study of medical marijuana discouraged". The New York Times. Archived from the original on 23 January 2010. Retrieved 22 February 2010.
  14. ↑ Stafford, Lindsay (February–April 2010), "The state of clinical cannabis research in the United States", HerbalGram, 85: 64–68, archived from the original on 2010-03-03, retrieved 2010-02-22
  15. ↑ Abrams DI; Vizoso HP; Shade SB; Jay C; Kelly ME; Benowitz NL (2007), "Vaporization as a smokeless cannabis delivery system: A pilot study", Clinical Pharmacology & Therapeutics, 82 (5): 572–578, doi:10.1038/sj.clpt.6100200, PMID   17429350, S2CID   14629288
  16. 1 2 LSD & Psilocybin-Assisted Therapy for Anxiety, Maps.org, archived from the original on 2012-04-14, retrieved 2012-04-14
  17. ↑ Psychedelic Research Around the World, Maps.org, archived from the original on 2013-12-03, retrieved 2012-04-14
  18. ↑ MAPS Bulletin Volume XX, 3, "2010 Annual Report"
  19. ↑ "Funding Priorities". Maps.org. Archived from the original on 2011-04-17. Retrieved 2011-04-20.
  20. ↑ MAPS Annual Financial Report, Fiscal Year 2009-2010 June 1, 2009 - May 31, 2010
  21. ↑ "MAPS' Annual Financial Reports". Maps.org. Archived from the original on 2011-04-17. Retrieved 2011-04-20.
  22. ↑ "Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval". MAPS. 2020-08-20. Archived from the original on 2020-08-24. Retrieved 2020-08-29.
  23. ↑ Ramachandran, Shalini (2020-08-20). "WSJ News Exclusive | Silicon Valley and Wall Street Elites Pour Money Into Psychedelic Research". Wall Street Journal. ISSN   0099-9660. Archived from the original on 2020-08-28. Retrieved 2020-08-29.
  24. ↑ Jag Davies. "Letting the Science, Not the Politicians, Decide About Marijuana | Drugs". AlterNet. Archived from the original on 2010-01-13. Retrieved 2010-03-17.
  25. ↑ MAPS Bulletin Volume XVI Number 3: Winter 2006-7, Maps.org, archived from the original on 2012-03-31, retrieved 2012-04-14
  26. 1 2 Department of Health and Human Services; National Institutes of Health; National Institute on Drug Abuse (January 1998). "NIDA - About NIDA - Organization - NACDA - Provision of Marijuana and Other Compounds For Scientific Research - Recommendations of The National Institute on Drug Abuse National Advisory Council". archives.drugabuse.gov. Archived from the original on April 12, 2014. Retrieved April 11, 2014.
  27. ↑ Weed Control Archived 2011-06-02 at the Wayback Machine Boston Globe May 28, 2006. Retrieved on February 15th 2010.
  28. ↑ Murphey, Lance (10 August 2016). "Obama Administration Set to Remove Barrier to Marijuana Research". New York Times. Retrieved 6 January 2021.
  29. ↑ National Medical Affairs Office. "DEA proposes process to expand marijuana research in the United States". Drug Enforcement Administration. Retrieved 6 January 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.